– The Company launched two campaigns at its site in Medchal and the upcoming site at
Muppireddipalli
Hyderabad, India, June 5, 2015 – In observance of World Environment Day, Sanofi Pasteur, the
vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its affiliate
Shantha Biotechnics in India launched two campaigns as part of its commitment to caring for the
environment.
The tree plantation drive started from the Medchal site with Dr. Harish Iyer, CEO – Shantha planted
the first sapling. More than 300 volunteers from Shantha took part in the campaign by planting trees
on both sides of the interior road between the site and the Medchal highway. The trees were
specifically chosen as they are easy to sustain and grow in the region.
Dr. Harish Iyer, said, “At Shantha, we are committed to sustainability, especially in environment
protection. We have adopted measures to ensure that our operations and employees both engage
in initiatives that preserve and protect the environment to benefit us and our future generations.
World Environment Day thus becomes an occasion to increase our efforts by educating employees
and involving them in environmentally friendly initiatives for the community.”
Another campaign aimed at creating a plastic-free community was kicked off at Shantha’s
Muppireddipalli site. More than 200 employees carried out a cleaning drive in and around the
Muppireddipalli Village by clearing all the plastic material on road, lanes and around houses. The
employee volunteers also distributed free reusable jute shopping bags to residents, encouraging
them to evolve into a plastic-free community. All the plastic waste that was collected was sent to the
designated waste disposal area, in coordination with the municipal authorities.
“These campaigns of planting trees and creating a cleaner community by clearing all plastic
materials and distributing jute bags, signifies our commitment to the planet by caring for the
environment.” Dr. Harish Iyer added.
About Shantha Biotechnics Limited
Shantha Biotechnics Limited, which was acquired by Sanofi Pasteur Holding in 2009, is a
biotechnology pioneer from the emerging countries, founded by Dr. K I Varaprasad Reddy in 1993
in Hyderabad, India. Shantha is a fully integrated biotechnology company involved in R&D,
manufacturing and marketing.
Shantha’s mission is to develop, produce and market human healthcare products that are
affordable and meet the highest International standards. Shantha’s products complement Sanofi
Pasteur’s portfolio. Four of its licensed vaccines are WHO-prequalified: Shan5™ pediatric vaccine,
Shanchol™ cholera vaccine, Shanvac-B® hepatitis B vaccine, and ShanTT™ tetanus vaccine.
Sanofi Pasteur and Shantha are also developing a new pediatric combination vaccine based on
Shan5 that will incorporate Sanofi Pasteur’s Inactivated Polio Vaccine (IPV) in order to secure polio
eradication.
About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic
solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven
growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY).
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each
year, making it possible to immunize more than 500 million people across the globe. A world leader
in the vaccine industry, Sanofi Pasteur offers a broad range of vaccines protecting against 20
infectious diseases. The company’s heritage, to create vaccines that protect life, dates back more
than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the
company invests more than EUR 1 million in research and development. For more information,
please visit: www.sanofipasteur.com or www.sanofipasteur.us
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These
statements include projections and estimates and their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future financial results, events, operations, services,
product development and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in
such forward-looking statements are reasonable, investors are cautioned that forward-looking information and
statements are subject to various risks and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties inherent in research and development, future
clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or biological application that may be filed
for any such product candidates as well as their decisions regarding labelling and other matters that could
affect the availability or commercial potential of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the future approval and commercial success
of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in
exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes
thereto, the average number of shares outstanding as well as those discussed or identified in the public filings
with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year
ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or statements.